Skip to main content
main-content
Top

12-06-2019 | Psoriatic arthritis | EULAR 2019 | Article

Researcher comment: Tildrakizumab shows promise for PsA

Lead investigator Philip Mease outlines the results of a phase IIb trial supporting further development of the anti-interleukin-23p19 monoclonal antibody tildrakizumab for the treatment of psoriatic arthritis (8:45).

More on this trial

News story | Tildrakizumab shows promise for PsA​​​​​​​

Related topics

Image Credits